Charles Schwab Investment Management Inc. Acquires 1,593 Shares of Surmodics, Inc. (NASDAQ:SRDX)

Charles Schwab Investment Management Inc. boosted its holdings in shares of Surmodics, Inc. (NASDAQ:SRDX) by 1.4% during the 4th quarter, Holdings Channel reports. The firm owned 117,904 shares of the company’s stock after buying an additional 1,593 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Surmodics were worth $4,669,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the business. Modus Advisors LLC purchased a new stake in Surmodics during the 4th quarter valued at approximately $40,000. Quest Partners LLC grew its stake in Surmodics by 107,100.0% during the third quarter. Quest Partners LLC now owns 1,072 shares of the company’s stock valued at $42,000 after acquiring an additional 1,071 shares in the last quarter. R Squared Ltd purchased a new position in Surmodics during the fourth quarter valued at $55,000. SG Americas Securities LLC increased its holdings in Surmodics by 22.1% in the 4th quarter. SG Americas Securities LLC now owns 6,940 shares of the company’s stock valued at $275,000 after acquiring an additional 1,255 shares during the last quarter. Finally, Algert Global LLC lifted its stake in Surmodics by 29.9% in the 3rd quarter. Algert Global LLC now owns 17,820 shares of the company’s stock worth $691,000 after purchasing an additional 4,098 shares in the last quarter. 96.63% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. StockNews.com started coverage on Surmodics in a research report on Monday, February 3rd. They set a “hold” rating for the company. Lake Street Capital upgraded Surmodics from a “hold” rating to a “buy” rating and set a $43.00 price target for the company in a report on Friday, March 7th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Surmodics in a research note on Thursday, January 30th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, Surmodics presently has a consensus rating of “Hold” and an average target price of $50.00.

Surmodics Stock Performance

Surmodics stock opened at $30.91 on Wednesday. The company has a quick ratio of 4.29, a current ratio of 5.45 and a debt-to-equity ratio of 0.26. Surmodics, Inc. has a twelve month low of $25.17 and a twelve month high of $42.44. The company’s 50-day moving average price is $33.24 and its 200-day moving average price is $36.91. The company has a market cap of $441.89 million, a PE ratio of -30.60 and a beta of 1.19.

Surmodics (NASDAQ:SRDX) last issued its quarterly earnings data on Thursday, February 6th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.04. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%. On average, equities research analysts forecast that Surmodics, Inc. will post 0.2 EPS for the current fiscal year.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).